{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:10:43Z","timestamp":1761919843407,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cancergen.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T16:00:58Z","timestamp":1400688058000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"207","author":[{"given":"Karl S.","family":"Theil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu V.","family":"Cotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2014.05.006_bib1","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2014.05.006_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.1995.tb05329.x","article-title":"Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study","volume":"91","author":"Secker-Walker","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergen.2014.05.006_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/AJCP48AJDCKTHUXC","article-title":"Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia","volume":"136","author":"Cui","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cancergen.2014.05.006_bib4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/modpathol.2010.210","article-title":"De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification","volume":"24","author":"Sun","year":"2011","journal-title":"Mod Pathol"},{"year":"2013","series-title":"ISCN 2013: an international system for human cytogenetic nomenclature","key":"10.1016\/j.cancergen.2014.05.006_bib5"},{"key":"10.1016\/j.cancergen.2014.05.006_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cancergencyto.2005.07.015","article-title":"The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction","volume":"165","author":"Han","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2014.05.006_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cancergen.2011.06.002","article-title":"Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors","volume":"204","author":"Paquette","year":"2011","journal-title":"Cancer Genet"},{"year":"2008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","key":"10.1016\/j.cancergen.2014.05.006_bib8"},{"key":"10.1016\/j.cancergen.2014.05.006_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/10428194.2012.701739","article-title":"Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia","volume":"54","author":"Konoplev","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergen.2014.05.006_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1309\/3HFE16DKMB1DBFMN","article-title":"inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases","volume":"124","author":"Merzianu","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cancergen.2014.05.006_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/10428194.2010.538941","article-title":"De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature","volume":"52","author":"Roth","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergen.2014.05.006_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1309\/H8JH6L094B9U3HGT","article-title":"t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia","volume":"121","author":"Yin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cancergen.2014.05.006_bib13","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/1097-0142(19841201)54:11<2409::AID-CNCR2820541117>3.0.CO;2-V","article-title":"Promyelocytic blast crisis of chronic myelocytic leukemia with both t(9;22) and t(15;17) in M3 cells","volume":"54","author":"Castaigne","year":"1984","journal-title":"Cancer"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776214000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:38:53Z","timestamp":1761896333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776214000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S2210776214000921"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.05.006","relation":{},"ISSN":["2210-7762"],"issn-type":[{"type":"print","value":"2210-7762"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic significance of an inv(3)(q21q26.2) in addition to a t(9;22)(q34;q11.2) in patients treated with tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}